KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Merck (MRK) EBIAT (2016 - 2026)

Merck has reported EBIAT over the past 18 years, most recently at -$4.2 billion for Q1 2026.

  • Quarterly EBIAT fell 183.48% to -$4.2 billion in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.9 billion through Mar 2026, down 48.74% year-over-year, with the annual reading at $18.3 billion for FY2025, 6.7% up from the prior year.
  • EBIAT was -$4.2 billion for Q1 2026 at Merck, down from $3.0 billion in the prior quarter.
  • Over five years, EBIAT peaked at $5.8 billion in Q3 2025 and troughed at -$6.0 billion in Q2 2023.
  • The 5-year median for EBIAT is $3.7 billion (2024), against an average of $2.7 billion.
  • Year-over-year, EBIAT crashed 251.5% in 2023 and then surged 407.08% in 2024.
  • A 5-year view of EBIAT shows it stood at $3.0 billion in 2022, then crashed by 140.24% to -$1.2 billion in 2023, then surged by 407.08% to $3.7 billion in 2024, then decreased by 20.55% to $3.0 billion in 2025, then crashed by 243.15% to -$4.2 billion in 2026.
  • Per Business Quant, the three most recent readings for MRK's EBIAT are -$4.2 billion (Q1 2026), $3.0 billion (Q4 2025), and $5.8 billion (Q3 2025).